Browse the evidence

Obtaining a home scale with advanced features (digital connectivity or high weight capacity >400 lbs) is significantly more expensive and less available than basic scales, creating a financial and accessibility barrier for patients requiring these specific features for self-weighing.

If you need to self-weigh but have a higher body weight or need to sync data with your doctor, basic scales may not work for you. These specialized scales cost significantly more ($40-$50+ vs $20-25). Talk to your clinician about whether insurance might cover the cost, or look for the most affordable option that meets your specific weight and connectivity needs.

Postprandial hypotension (PPH), defined as a systolic BP drop of ≥20 mmHg within 2 hours of eating, is an independent predictor of all-cause mortality, syncope, angina, and stroke, particularly in the elderly.

If you experience dizziness, fainting, or significant fatigue after meals, especially if you are older or have diabetes, consult a doctor. This could be postprandial hypotension, a risk factor for stroke and falls.

A 2-week exposure to either a low-carbohydrate (LC) or low-fat (LF) diet does not significantly alter sweet or salty taste detection thresholds or preferences compared to each other.

Switching to a low-carb or low-fat diet for just two weeks will not change your taste buds or your cravings for sweet and salty foods. If you are expecting your food preferences to shift quickly as a result of the diet itself, this short timeframe is likely too short to observe such changes.

Consuming ultra-processed milkshakes high in fat and sugar does not produce a statistically significant average increase in postingestive striatal dopamine release in healthy adults, refuting the hypothesis that such foods elicit drug-like dopamine responses.

The idea that ultra-processed foods trigger a massive, drug-like dopamine spike in your brain is not supported by this research. While individual responses vary, the average brain does not show a significant dopamine release after eating these foods. This suggests that overconsumption is likely driven more by behavioral factors, hunger, and hedonic preference (how much you like/want the food) rather than a fixed, overpowering biological addiction mechanism.

Adiposity (BMI, body fat percentage) is not significantly correlated with the magnitude of postingestive striatal dopamine response to ultra-processed foods, contradicting the hypothesis that obesity blunts this response.

Your body fat percentage does not determine how much your brain releases dopamine when you eat. This study found no link between being overweight and a 'blunted' dopamine response. This is encouraging: it means your brain's reward system is not permanently damaged by your weight, and you can influence your food preferences and intake through behavioral strategies.

Higher baseline BMI (30–40 kg/m²) correlates with lower health-related quality of life (utility indices), but the effect size is small (up to 0.005 per unit BMI) and often not statistically significant, suggesting BMI alone does not explain HRQoL differences.

While higher BMI is associated with slightly lower health utility scores, the impact is small and often not statistically significant. Do not assume your quality of life is defined by your BMI alone. Focus on managing specific comorbidities, age-related changes, and mental health, as these appear to be stronger drivers of your daily well-being than BMI itself.

Existing patient-reported outcome (PRO) measures for obesity fail to capture key appetite and eating behavior concepts (e.g., duration of fullness, satisfaction after eating, eating between meals) that are relevant to individuals with obesity and likely to change with treatment.

If you are managing obesity, standard questionnaires might miss how you actually feel after eating (satisfaction, fullness duration). This gap means your provider might not fully understand your specific challenges with cravings or portion control. A comprehensive assessment tool (like the EBAQ) can better capture these nuances to tailor your treatment plan.

Primary care physicians systematically overestimate the mortality risk associated with being overweight (BMI 25–29.9), perceiving a significantly higher risk increase than what current meta-analytic evidence supports.

Physicians should be aware that their perception of mortality risk for overweight patients (BMI 25-29.9) is likely inflated compared to actual population data. This overestimation may lead to unnecessary alarm or aggressive interventions for patients who are not obese. Counseling should focus on overall health metrics rather than BMI categories alone, recognizing that the mortality risk for 'overweight' is modest and inconsistent across studies.

DPP-4 inhibitors (Sitagliptin, Saxagliptin, Alogliptin, Linagliptin) are generally neutral for cardiovascular outcomes, with specific agents (Saxagliptin, Alogliptin) associated with an increased risk of heart failure hospitalization.

If you have Type 2 Diabetes and Heart Failure, avoid Saxagliptin and Alogliptin. DPP-4 inhibitors are generally neutral for heart health; prefer SGLT2 inhibitors or GLP-1 agonists which offer proven cardiovascular benefits.

In Japanese subjects, obesity (higher BMI) reduces the numerical incretin effect more significantly than glucose intolerance (T2D or IGT status).

If you have Type 2 Diabetes or pre-diabetes, focus on weight management to improve your body's natural hormonal response to food. In Japanese populations, losing weight improves the 'incretin effect' (how your gut signals your pancreas to make insulin) more effectively than just managing blood sugar numbers alone.

Gastrointestinally-mediated glucose disposal (GIGD), a measure of integrated glucose handling including glucagon suppression, is significantly reduced in Type 2 Diabetes and correlates with obesity.

Managing Type 2 Diabetes involves more than just stimulating insulin; it requires suppressing glucagon. Weight loss helps restore this balance, improving how your body disposes of glucose after a meal.

Leucine-rich high protein supplementation (50.6 g protein and 6 g leucine daily) does not significantly improve body composition or muscle function in older adults with sarcopenia over a 12-week period, despite upregulating specific gene expression related to ATP production and DNA repair.

For older adults with sarcopenia, taking leucine-rich protein supplements alone for 12 weeks will not significantly increase muscle mass or improve physical function. While it may positively influence gene expression related to energy production, it is not a standalone solution for reversing sarcopenia. To see functional benefits, supplementation should likely be combined with resistance exercise.

Telephone health coaching (THC) does not significantly reduce long-term (8-year) composite cardiovascular morbidity or mortality in intention-to-treat analysis for patients with Type 2 Diabetes, Coronary Artery Disease, or Congestive Heart Failure.

If you have diabetes or heart disease, phone coaching alone is unlikely to prevent heart attacks or death unless you actively engage with the process. The study showed no benefit for the general group receiving the coaching. However, those who actually participated in the sessions (per-protocol) did see benefits, suggesting that your active involvement is the key driver, not the phone calls themselves.

In elderly patients with type 2 diabetes, maintaining the Triglyceride-Glucose index combined with a Body Shape Index (TyG-ABSI) within an optimal range (specifically avoiding both extremely low and extremely high values) is associated with the lowest all-cause mortality risk.

If you have Type 2 Diabetes, standard weight metrics like BMI might not fully capture your mortality risk. Research suggests that a combination of insulin resistance markers (Triglyceride-Glucose index) and body shape (ABSI) provides a more accurate prediction of health outcomes. Crucially, this risk follows a 'U-shape': both extremely high and extremely low values of this combined index are associated with higher mortality. Therefore, the goal is not simply to minimize these numbers, but to maintain them within an optimal, balanced range, while closely monitoring kidney function (eGFR) as it mediates this risk.

Intensive lifestyle intervention (diet and exercise) fails to reduce cardiovascular disease or mortality in type 2 diabetic patients because long-term weight loss cannot be sustained in real-world clinical settings.

Strict diet and exercise programs are unlikely to prevent heart attacks or death in diabetics if you cannot maintain them for years. Focus on consistent, moderate lifestyle habits and optimal medical management of risk factors instead of chasing extreme weight loss.

Obesity causes chronic kidney disease directly through adaptive glomerular changes (glomerulopathy associated with obesity) and indirectly by increasing the risk of hypertension and type 2 diabetes.

Maintaining a healthy weight is critical for kidney health. Obesity directly stresses the kidneys through increased blood flow and filtration pressure, leading to scarring (glomerulosclerosis). Weight loss, along with managing blood pressure and blood sugar, is the most effective way to prevent kidney damage.

Hypothalamic gliosis, measured via MRI T2 signal ratios, is positively associated with higher BMI, hypertension, metabolic syndrome, and lower HDL-C, independent of adiposity.

This research suggests that brain inflammation (gliosis) is linked to heart disease risks like high blood pressure and bad cholesterol, even if you aren't overweight. While you can't easily see this on an MRI, it implies that managing metabolic health through diet and exercise might protect your brain's regulatory centers, potentially lowering your cardiovascular risk.

Approximately 11.5% of patients undergoing secondary metabolic bariatric surgery (MBS) transfer to a different hospital than their primary procedure, a rate that is underestimated in single-institution registries.

If you are considering secondary bariatric surgery, be aware that about 11% of patients switch hospitals for this procedure. This is often driven by dissatisfaction with weight regain or complications from the first surgery. You are not alone in seeking a second opinion or a different provider if you feel your current care is not meeting your expectations.

Obesity causes kidney damage through direct mechanisms including glomerular hyperfiltration, increased intraglomerular pressure, and the endocrine activity of adipose tissue, independent of diabetes and hypertension.

Your kidneys are working harder because of your weight. The extra fat tissue releases hormones that increase pressure inside the kidney's filtering units. This constant high pressure damages the filters over time, leading to kidney disease. Managing your weight reduces this internal pressure and protects kidney function.

SGLT2 inhibitors improve cardiac energy efficiency in failing diabetic hearts by shifting fuel utilization from fatty acids to ketone bodies, which act as a 'super-fuel' that generates ATP more efficiently.

SGLT2 inhibitors change how your heart gets energy. Instead of struggling to burn fat, your heart efficiently burns ketones produced by the drug, which provides more energy with less stress, helping a failing heart function better.

Higher neighborhood-level socioeconomic disadvantage is associated with weaker statistical interactions (correlations) among the stages of adiposity, dysglycemia, and hypertension, suggesting that in disadvantaged populations, these cardiometabolic drivers develop more independently of one another.

If you live in a high-disadvantage neighborhood, standard assumptions about how weight affects blood sugar and blood pressure may not apply to you. The link between carrying extra weight and developing high blood sugar or high blood pressure is weaker in these settings. This suggests that factors like chronic stress, limited access to healthy food, and environmental stressors play a larger, independent role in your cardiometabolic health. Screening and prevention strategies should account for these social determinants rather than focusing solely on weight management.

Elevated Remnant Cholesterol Inflammatory Index (RCII) is independently associated with a significantly higher risk of incident cardiovascular disease (CVD), including heart disease and stroke.

If you are over 45, ask your doctor about your Remnant Cholesterol Inflammatory Index (RCII). It combines your cholesterol levels with inflammation markers to better predict heart disease risk than weight or BMI alone. High RCII indicates a need for targeted lifestyle interventions focusing on both lipid management and inflammation reduction.

RCII partially mediates the association between ABSI and incident CVD, with the mediation proportion increasing across higher ABSI quartiles.

Understanding that inflammation and lipid metabolism (RCII) play a role in how abdominal fat (ABSI) affects heart health can guide more targeted treatments. For those with high ABSI, addressing inflammation may provide additional cardiovascular protection beyond just weight management.

Prolonged oral processing (chewing) increases in vitro protein and lipid digestion efficiency by mechanically breaking down the food matrix, but this does not necessarily translate to altered in vivo glycaemic responses in healthy individuals.

For healthy individuals, chewing your food more thoroughly will help your stomach enzymes break down proteins and fats more efficiently in the lab setting, but it won't significantly change your blood sugar levels or metabolic health. If you have pre-diabetes, thorough chewing may help regulate blood sugar, but for the general healthy population, the food's physical structure (e.g., whole nuts vs. ground) matters more for nutrient absorption than chewing time alone.